Raymond James Downgrades NGM Biopharmaceuticals (NGM) to Market Perform 'Due to Possible Going Private Transaction'
Tweet Send to a Friend
(Updated - March 12, 2024 3:44 AM EDT)Raymond James analyst Steven Seedhouse downgraded NGM Biopharmaceuticals (NASDAQ: NGM) from Outperform to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
